Skip to main content
. 2020 May 24;18:39. doi: 10.1186/s12969-020-00431-y

Table 1.

neurological and nephrological manifestation in childhood Sjogren syndrome

Case 1 2 3 4 5 6 7 8 9 10 11
References/Year Matsui [2] Kornitzer [3] Arabshahi [4] Bogdanovic [5] Kumon [6] Pessler [7] Jung [8] Igarashi [9] Gottfried [10] Wong [11] Kagan [12]
Age (Gender) 9/F 6/F 11/F 13/F 14/F 6/F 11/F 12/F 9/F 16/F 12/F
Symptoms at onset fever fever headache optic neuritis nephrocalcinosis fever arthralgia parotitis

hematuria

proteinuria

parotitis

fever

conjunctivitis

headache AKI
Dry eyes or mouth NM N NM NM NM NM Y Y Y N NM
Parotitis NM NM NM Y N NM N Y Y Y Y
Neurologic manifestation

mental disorder

gaze deviation

ambulation difficulty

mental disorder

muscle weakness

muscle weakness

urinary incontinence

N

arm numbness

hypalgesia

thermohypoesthesia

N N N

Ambulation

difficulty

ptosis

leg numbness

dysarthria,

ataxia

N
Renal damage RTA N N

dRTA

diabetes insipidus

N RTA

dRTA

hematuria

proteinuria

proteinuria N N

hematuria

proteinuria

ANA Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
Anti-Ro/SSA Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
Anti-Lo/SSB Neg Neg Pos Neg Pos Pos Neg Pos Neg Pos Neg
ESR NM NM NM NM Pos Pos NM Pos Neg Pos NM
RF Pos Neg Neg Pos Pos Pos NM NM Neg NM Neg
Hyperglobulinemic IgG IgM NM NM NM IgG NM N IgG IgA IgM NM NM NM
Schirmer test Neg Neg Pos Neg Neg NM Pos Pos Neg NM NM
CSF Pos Pos Pos NM Pos NM NM NM Neg Pos NM
Renal biopsy NM NM NM TIN NM GS TIN IgA TIN NM NM

crescentic GN

TIN

Salivary gland biopsy Pos Pos Pos NM Pos NM NM Pos Pos NM NM
Immunomodulatory therapy GC GC AZA RTX GC CTX GC AZA MMF GC

GC CTX

MMF

GC GC GC GC GC AZA
Outcome residual dysphagia

right-side&facial

nerve weakness

vision loss

stable renal

function

sensory disturbance

stable renal

function

recover stable

residual ptosis

facial diplegia

recover

normal renal

function

Follow up (yr) 7 m 3 0.5 6 NM 7 4 m NM 6 m 3w 1
Case 12 13 14 15 16 17 18 19 20 21
References/Year DeGuzman [13] Skalova [14] Yoshida [15] Berman [16] Zawadzki [17] Kobayashi [18] Chang [19] Ohlsson [20] Hoshina [21] Present patient
Age (Gender) 14/M 16/F 13/M 10/F 15/F 10/F 11/F 15/F 8/F 16/F 12/F
Symptoms at onset fever seizure muscular weakness

hematuria

proteinuria

fever headache

dizziness vomiting

gait disturbances uveitis fever weakness arthritis

fever headache

vomiting

joint pain
Dry eyes or mouth N N N NM NM N N Y NM Y Y
Parotitis N NM N NM NM Y Y Y NM Y N
Neurologic manifestation

muscle weakness

slurred speech

muscle weakness N

dysmetria weakness

proprioception

N N N N N N

superficial sensation

impaire

Renal damage Neg

dRTA

proteinuria

hematuria

proteinuria

N dRTA dRTA N dRTA

dRTA

proteinuria

N glucosuria
ANA Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
Anti-Ro/SSA Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Neg
Anti-Lo/SSB Neg Pos Pos Pos Pos Neg Pos Neg Pos Pos Pos
ESR NM Pos NM Pos NM Pos Pos Pos Pos NM Pos
RF NM Pos NM Pos NM Pos Pos Pos Pos Pos Neg
Hyperglobulinemic IgG IgG N IgG IgG IgA IgM IgG IgM IgG IgA IgG1 IgG N
Schirmer test NM NM NM NM Neg Pos Neg Pos NM Pos Pos
CSF Pos NM NM Pos NM NM Pos NM NM Pos Neg
Renal biopsy NM TIN MGN NM TIN TIN NM NM NM NM TIN
Salivary gland biopsy Pos NM Pos Pos Pos Pos NM Neg NM NM Pos
Immunomodulatory therapy GC CTX GC CSA GC GC CTX GC CTX GC CTX GC NM GC HCQ MTX GC TAC HCQ GC
Outcome

lethargic

visual impairment

difficulty walking

recover

urine protein

hematuria

stable tubular acidosis stable stable NM synovitis

symptoms

improved

glucosuria
Follow up (yr) 3 1 m 2 m 11 m 14 m 5 3 3 2 m NM 1.5

*F female; M male; Y yes; N no; m months; w weeks; NM not mention; Neg negative; Pos positive; GC glucocorticoid; AZA azathioprine; RTX rituximab; HCQ hydroxychloroquine; CTX cyclophosphamide; MMF mycophenolate mofetil; MTX methotrexate; CSA cyclosporine A; TAC tacrolimus